SLC7A5 and colorectal cancer: For instance, the inhibition of Glut2 (Slc2a2) dynamics has the potential to improve diabetes mellitus in mice (21), and Slc7A5, a glutamine antiporter, could be an attractive target for therapy-resistant, KRAS-mutant colorectal cancer in mice (66).